Characterizing FOLR1 expression in Low Grade Serous Ovarian Carcinoma


Tullia Rushton, Harris Krause, Andrew Elliott, Anthony Karnezis, Michael Toboni, Premal Thaker, David Braxton, Matthew Oberley, David Gershenson, Deborah Armstrong


  • Targeted therapy in folate receptor alpha (FOLR1)-positive high grade serous ovarian carcinoma (HG) is now a mainstay for platinum-resistant disease.
  • The rate of FOLR1-positivity in low grade serous ovarian carcinoma (LG) is unknown.
  • We compared the genomic and transcriptomic landscapes in FOLR1-positive/negative LG in comparison to its HG counterpart.
Download Publication